All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
MagnetisMM-3: Long-term survival after elranatamab monotherapy in patients with RRMM
Bookmark this article
|
Data from the phase II MagnetisMM-3 trial (NCT04649359) demonstrates deep and durable responses to elranatamab monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). In the BCMA-naive arm (Cohort A; n = 123), the primary endpoint of overall response rate (ORR) was 61% at a median follow-up of 17.6 months. Updated results in BCMA-naive patients after 2 years of follow-up were presented by Mohamad Mohty at the European Hematology Association (EHA) 2024 Hybrid Congress.1
|
| Key learnings: |
| In the phase II MagnetisMM-3 trial, the ORR remained at 61% after >2 years of follow-up, with 37.4% of patients achieving ≥CR. |
| The rate of MRD negativity was 90.3% in evaluable patients achieving ≥CR (n = 31). |
| The median PFS was 17.2 months, and the median OS was 24.6 months. |
| The median duration of response was not reached; the probability of maintaining at response at 2 years was 66.9% for all responders and 87.9% in patients achieving ≥CR. |
| No new safety signals were observed. A small number of secondary primary malignancies (SPMs) (<5%) and no hematologic SPMs were reported. |
| These findings demonstrate the durable long-term efficacy of elranatamab in heavily pretreated patients with BCMA-naive RRMM and supports the continued evaluation of the efficacy and safety of elranatamab across patient populations with MM. |
- Mohty M. Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MAGNETISMM-3. Poster #P932. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16, 2024; Madrid, ES.
Your opinion matters
3 votes - 46 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox